<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03296761</url>
  </required_header>
  <id_info>
    <org_study_id>2017ZDSYLL081-P01</org_study_id>
    <nct_id>NCT03296761</nct_id>
  </id_info>
  <brief_title>Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury</brief_title>
  <official_title>Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jingyuan,Xu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the changes of plasma ESM-1 levels in patients with ARDS, and to explore its
      clinical significance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      70 patients who diagnosed as ARDS were included in this study. Then keep blood samples from
      these patients in the first day, the third day and the seventh day, detect ESM-1 level in
      plasma by ELISA. Record Severity of illness and survival status of every patient within 28
      days. Objective to evaluate the correlation between the level of ESM-1 in plasma and the
      prognosis of the patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">February 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>28-day</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Evaluate the Correlation Between the Level of ESM-1 and the Prognosis of the Patients With ARDS</condition>
  <arm_group>
    <arm_group_label>ESM-1＜5ng/ml</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ESM-1≥5ng/ml</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Population admitted to ICU of Zhongda hospital ，diagnosed of ARDS
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients admitted to ICU diagnosed of ARDS (Berlin definition）in 48h

          2. Patients age between 18 years old and 80 years.

        Exclusion Criteria：

          1. Pregnant women,

          2. Patients with malignant tumor,

          3. Immunosuppression or immunocompromised patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haibo qiu</last_name>
    <role>Study Chair</role>
    <affiliation>Zhong-Da Hospital, School of Medicine, Southeast University,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuanyuan YU</last_name>
    <phone>15651680953</phone>
    <email>220153911@seu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haibo qiu</last_name>
    <phone>+862583262550</phone>
    <email>haiboq2000@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing Zhongda Hospital, School of Medicine, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanyuan YU</last_name>
      <phone>15651680953</phone>
      <email>220153911@seu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Jingyuan,Xu</investigator_full_name>
    <investigator_title>chief doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

